A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Severe Asthma

In brief

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).

Key facts

Study ID
NCT06966479
Run by
Upstream Bio Inc.
People needed
396
Starts
2025-05-21
Expected to finish
2027-09-01
Last updated by the study team
2026-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.